James Edgemond

CFO James Edgemond sells 8,750 shares at $534.06–$541.25 for $4.7M under 10b5-1 plan; retains 18,876 shares

CFO James Edgemond executed 8 separate sales totaling 8,750 shares for $4,708,785.65 under a pre-arranged 10b5-1 trading plan, reducing his direct holdings by 31.7% to 18,876 shares. The blended average price of $538.15 trades just below the current market price of $544.33, placing the transaction near recent levels with the stock down 4.2% over 30 days and down 10.7% from its 52-week high of $609.35. This is the latest in a pattern of regular sells by this insider; his same-ticker history shows 5 prior sales on 2026-06-11, and he has executed 20 prior open-market sales across all tickers. As a scheduled 10b5-1 transaction, this sale reflects a pre-committed trading schedule rather than a discretionary trading decision, and the insider retains a material position of 18,876 shares.

CFO James Edgemond sells 10,000 shares for $5.4M via scheduled plan, retains 18,876 shares plus 8,750 stock options.

James Edgemond, CFO and Treasurer of United Therapeutics, executed 14 separate sales totaling 10,000 shares for $5,401,488.51 on 2026-06-18 at prices ranging from $533.59 to $547.37, with a blended average price of $540.15. This transaction is part of a pre-arranged 10b5-1 trading plan and therefore represents scheduled, discretionary-neutral activity. The sale reduces his non-derivative holdings by 34.6%, from 28,876 shares to 18,876 shares, but his overall position remains substantial when accounting for 8,750 stock options held in Table II derivative securities. Notably, Edgemond executed similar sell activity just one week prior on 2026-06-11 (5 prior same-ticker sales with outcomes not yet measurable). The stock is trading at $538.30 currently, approximately 11.7% below its 52-week high of $609.35, and has declined 5.3% over the past 30 days despite the company's solid fundamentals—$781.5M quarterly revenue, net income of $274.9M, and 10.6% annual revenue growth.

CFO James Edgemond sells 10,000 shares at $5.5M under 10b5-1 plan; retains 18,876 shares post-sale

James Edgemond, CFO and Treasurer, executed 14 separate sales totaling 10,000 shares for $5,491,742.08 on 2026-06-15 at prices ranging from $538.52 to $550.89, with a blended average price of $549.17. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled and non-discretionary. Post-transaction, Edgemond holds 18,876 shares, down from 28,876 shares prior to the sale, representing a -34.6% reduction in his non-derivative holdings at this ticker. The current stock price of $548.27 is -10.0% from the 52-week high of $609.35 and has declined -3.6% over the past 30 days, though it is +3.4% over 90 days. As a scheduled plan execution rather than a discretionary trade, this sale reflects contractual commitment rather than a market-timing decision by the executive.

CFO James Edgemond sold 10,000 shares at $549.29 avg price on 2026-06-11 via pre-arranged 10b5-1 plan; retains 18.9K shares post-sale

James Edgemond, CFO and Treasurer of United Therapeutics, executed 9 separate sales totaling 10,000 shares for $5,492,893.89 on 2026-06-11, reducing his non-derivative holdings from 28.9K to 18.9K shares (a 34.6% reduction). This filing is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary. The blended average sale price of $549.29 compares to a current price of $545.40, slightly below the transaction prices. The company's fundamentals remain solid: annual revenue growth of 10.6%, a P/E of 17.98, and net income of $274.9M on revenue of $781.5M. Notably, Edgemond retains 10,000 shares of unexercised stock options (Table II derivative holdings), indicating his total economic exposure to the company continues.

CFO James Edgemond sold 10,000 shares for $5.5M via 8 transactions on 2026-06-08 under 10b5-1 plan; retains 18,876 shares plus 20,000 stock options

James Edgemond, CFO and Treasurer of United Therapeutics, executed 8 separate sales totaling 10,000 shares for $5,475,044.88 at a blended average price of $547.50 on 2026-06-08, as part of a pre-arranged 10b5-1 trading plan. This represents a -34.6% reduction versus his pre-transaction holdings of 28,876 shares; he retains 18,876 non-derivative shares post-sale plus 20,000 stock options. The stock's 52-week range is $272.12–$609.35, with the transaction priced near the upper bound but currently trading at $544.69, down -10.6% from the 52-week high and -3.6% over the last 30 days. Across his broader cross-ticker open-market history, his prior sells averaged +0.4% returns at both 30-day and 90-day horizons, while his same-ticker history at UTHR shows mixed outcomes (prior five sales at this ticker returning between -0.1% and +1.9% at both intervals). Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it signals neither timing acumen nor underlying conviction; the sale is autonomous and pre-established, separate from market conditions or fundamental judgment.

CFO James Edgemond sells 10,000 shares of UTHR for $5.5M via scheduled 10b5-1 plan; retains 18,876 shares plus 30,000 options.

James Edgemond, CFO and Treasurer of United Therapeutics, executed 10 separate sales totaling 10,000 shares for $5,462,824.46 on 2026-06-04 at prices ranging from $539.64 to $550.48, with a blended average of $546.28. This represents a 34.6% reduction in his non-derivative holdings (from 28,876 to 18,876 shares), executed via a pre-arranged 10b5-1 trading plan that operates on a scheduled, non-discretionary basis. His cross-ticker track record shows an average 90-day return of -4.0% following prior sales, while his five prior sales at UTHR specifically (all on 2026-05-28) show 90-day returns ranging from -3.0% to -4.7%. The stock is currently trading at $549.87, near the upper end of the transaction price range and -9.8% from its 52-week high of $609.35. Notably, Edgemond retains 30,000 shares in stock option holdings, preserving meaningful exposure to the company alongside his reduced non-derivative position.

CFO James Edgemond sells 10,000 shares at $5.5M via scheduled 10b5-1 plan; retains 18,876 non-derivative shares plus 40,000 stock options

James Edgemond, CFO and Treasurer, executed 9 separate sales totaling 10,000 shares for $5,478,663.36 on 2026-06-01, pursuant to a pre-arranged 10b5-1 trading plan. The blended average price across all transactions was $547.87, compared to the current price of $540.05. His non-derivative holdings decline from 28,876 shares to 18,876 shares post-transaction, a reduction of 34.6% relative to pre-transaction holdings, though derivative holdings of 40,000 stock options remain intact. Across his cross-ticker track record, his prior sells averaged 90-day returns of -4.0%, while his same-ticker history at UTHR shows five prior sells on 2026-05-28 averaging 90-day returns between -3.0% and -4.7%. As this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing of the sales does not reflect real-time market judgment but rather a pre-established schedule.

CFO sells 10,000 shares ($5.7M) in 10 tranches via scheduled 10b5-1 plan; retains 18,876 shares plus 50,000 options.

James Edgemond, CFO and Treasurer of United Therapeutics, executed 10 separate sales totaling 10,000 shares for $5,656,298.33 on 2026-05-28 at prices ranging from $561.48 to $570.50 (blended average $565.63). This transaction is part of a pre-arranged 10b5-1 trading plan, indicating scheduled execution rather than discretionary timing. Post-transaction, Edgemond retains 18,876 non-derivative shares (down 34.6% from 28,876 prior) plus 50,000 stock option holdings, meaning his overall economic exposure to UTHR remains substantial. His prior sales at UTHR show mixed near-term outcomes (90-day returns ranging from +0.1% to -0.8%), with no clear directional signal; his cross-ticker track record shows minimal average returns (-1.0% over 90 days after prior sells). The stock currently trades at $556.82, down 8.6% from its 52-week high of $609.35, suggesting he sold shares when prices were elevated relative to recent lows but below peak levels.

CFO James Edgemond executes 15 sales totaling 10,000 shares for $5,729,358.55 under 10b5-1 plan

CFO James Edgemond sold 10,000 shares on 2026-05-26 across 15 separate transactions at prices ranging from $559.58 to $577.13, with a blended average of $572.94. This sale reduced his non-derivative holdings to 18,876 shares (-34.6% vs pre-transaction level of 28,876 shares), though derivative holdings of 60,000 stock options remain. The trade is part of a pre-arranged 10b5-1 trading plan, meaning the execution was scheduled rather than discretionary. His cross-ticker track record across 20 prior sells shows an average 90-day return of -1.0%, while his 5 same-ticker sales at UTHR show mixed near-term performance ranging from -0.8% to +0.1%. The company's fundamentals remain solid with $274.9M in net income and +10.6% annual revenue growth, and the stock is currently -5.1% from its 52-week high of $609.35.

CFO James Edgemond sold 10,000 shares (34.6% of holdings) for $5.6M via 7 scheduled transactions under a 10b5-1 plan

James Edgemond, CFO and Treasurer of United Therapeutics, executed 7 separate sales totaling 10,000 shares for $5,641,130.12 on 2026-05-21, reducing his holdings from 28.9K to 18.9K shares. The sales occurred at prices ranging from $557.85 to $566.12, with a blended average of $564.11, compared to the current price of $568.43. This sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was scheduled rather than discretionary. His prior trades at UTHR show a mixed return pattern, with 30d and 90d returns clustering near -0.5% to +0.1%, while his broader cross-ticker track record shows an average 90d return of -1.0% on prior sells.